Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

Abstract: The disclosure describes example systems and techniques for controlling microstructure of a superalloy substrate by controlling temperature during forging and using multiple die forging stages to formation of grain boundary phases of the superalloy, and components formed by such example systems and techniques. The method includes heating a substrate to within a forging temperature range. The substrate includes a nickel-based superalloy, and the forging temperature range is below an eta phase solvus temperature of the substrate. The method includes applying a plurality of die forging stages to the substrate to form a component preform. The method includes maintaining the substrate within the forging temperature range during application of the plurality of die forging stages and cooling the component preform.

Abstract: The present disclosure provides a downstream manufacturing method for the production of bispecific antigen-binding molecule products, which comprise at least two different binding domains. The process comprises at least one filtration step, wherein the filtration is ultrafiltration/diafiltration (UF/DF), and/or viral filtration (VF), wherein a ?-cyclodextrin is applied in the process either in a buffer applied in the filtration step or added to the filtration pool after the UF/DF filtration step wherein the buffer or the pool have a concentration of about 0.1 to 3% (m/v) of a (3-cyclodextrin, to preferably keep the product in a non-aggregated form.

Abstract: The disclosure describes example systems and techniques for controlling microstructure of a superalloy substrate by controlling temperature during forging and using multiple die forging stages to formation of grain boundary phases of the superalloy, and components formed by such example systems and techniques. The method includes heating a substrate to within a forging temperature range. The substrate includes a nickel-based superalloy, and the forging temperature range is below an eta phase solvus temperature of the substrate. The method includes applying a plurality of die forging stages to the substrate to form a component preform. The method includes maintaining the substrate within the forging temperature range during application of the plurality of die forging stages and cooling the component preform.

Abstract: An example system may include a computing device including a finite element analysis module solving for a finite element model representing a component including a metal or an alloy and including a plurality of respective elements. The finite element analysis module may solve a respective stress St and a respective temperature Tt at each respective element during the predetermined cooling operating. The finite element analysis module may determine a respective impact energy ET based on the temperature Tt and cooling rate, using a predetermined cooling rate-dependent energy relationship that relates a temperature of the metal or the alloy to an impact energy, determine a respective weakness index Wt=[A×ET/St]n (A being a predetermined constant, n being a predetermined real number greater than or equal to 1), and identify a respective element having a minimum weakness index less than a predetermined weakness index threshold as a cracking-prone element.

Abstract: An example system may include a computing device including a finite element analysis module solving for a finite element model representing a component including a metal or an alloy and including a plurality of respective elements. The finite element analysis module may solve a respective stress St and a respective temperature Tt at each respective element during the predetermined cooling operating. The finite element analysis module may determine a respective impact energy ET based on the temperature Tt and cooling rate, using a predetermined cooling rate-dependent energy relationship that relates a temperature of the metal or the alloy to an impact energy, determine a respective weakness index Wt=[A×ET/St]n (A being a predetermined constant, n being a predetermined real number greater than or equal to 1), and identify a respective element having a minimum weakness index less than a predetermined weakness index threshold as a cracking-prone element.

Abstract: Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to a mammal in need thereof. Additionally disclosed are methods of preventing, inhibiting or treating thrombosis in a mammal in need of such prevention, inhibition or treatment comprising administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to the mammal.

Abstract: Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease among other conditions. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to a mammal in need thereof. Additionally disclosed are methods of preventing, inhibiting or treating thrombosis in a mammal in need of such prevention, inhibition or treatment comprising administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to the mammal.

Abstract: Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to a mammal in need thereof. Additionally disclosed are methods of preventing, inhibiting or treating thrombosis in a mammal in need of such prevention, inhibition or treatment comprising administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to the mammal.

Abstract: Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin D analogs to a mammal in need thereof.